Literature DB >> 16240152

[Angioedema due to ACE inhibitors and AT(1) receptor antagonists].

M-C Hellebrand1, G Kojda, T K Hoffmann, M Bas.   

Abstract

Acute drug-induced angioedema is a non-pruritic swelling of subcutaneous and submucosal tissue. It most occur occurs the mouth and larynx as well as lips and eyelids; less often other skin regions or even the gut can be involved. ACE inhibitor (ACEi)- induced angioedema typical occurs after several years on medication. A 72-year-old woman developed recurrent ACEi-induced angioedema. The drug was stopped and she received an AT(1)-receptor antagonist as an alternative antihypertensive. This medication also led to angioedema, which was not immediately recognized as medication-associated. AT(1)-receptor antagonists are not suitable alternatives for ACEi because they also carry an increased risk for inducing angioedema.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16240152     DOI: 10.1007/s00105-005-1046-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  9 in total

1.  Vasopeptidase inhibition and angio-oedema.

Authors:  F H Messerli; J Nussberger
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

2.  Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.

Authors:  A G Chiu; E J Krowiak; Z E Deeb
Journal:  Laryngoscope       Date:  2001-10       Impact factor: 3.325

3.  [Hereditary angioedema in the German-speaking region].

Authors:  H D Göring; K Bork; P J Späth; R Bauer; A Ziemer; H Hintner; B Wüthrich
Journal:  Hautarzt       Date:  1998-02       Impact factor: 0.751

4.  Losartan increases bradykinin levels in hypertensive humans.

Authors:  Duncan J Campbell; Henry Krum; Murray D Esler
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

5.  Plasma bradykinin in angio-oedema.

Authors:  J Nussberger; M Cugno; C Amstutz; M Cicardi; A Pellacani; A Agostoni
Journal:  Lancet       Date:  1998-06-06       Impact factor: 79.321

6.  Increased C-reactive protein in ACE-inhibitor-induced angioedema.

Authors:  M Bas; T K Hoffmann; H Bier; G Kojda
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

Review 7.  ACE inhibitor-induced angioedema. Incidence, prevention and management.

Authors:  W Vleeming; J G van Amsterdam; B H Stricker; D J de Wildt
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

8.  Angioedema due to angiotensin-converting enzyme inhibitors.

Authors:  A Agostoni; M Cicardi; M Cugno; L C Zingale; D Gioffré; J Nussberger
Journal:  Immunopharmacology       Date:  1999-10-15

Review 9.  Drug-induced angioedema without urticaria.

Authors:  A Agostoni; M Cicardi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

  9 in total
  6 in total

1.  [Angiotensin-converting enzyme inhibitor induced angioedema : new therapy options].

Authors:  M Bas; G Kojda; K Stelter
Journal:  Anaesthesist       Date:  2010-10-06       Impact factor: 1.041

Review 2.  [Drug-induced angioedema : Focus on bradykinin].

Authors:  B Sachs; T Meier; M M Nöthen; C Stieber; J Stingl
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

Review 3.  [Angioedema].

Authors:  H F Merk
Journal:  Hautarzt       Date:  2007-12       Impact factor: 0.751

4.  [Angioneurotic orolingual edema associated with the use of rt-PA following a stroke].

Authors:  R Laubinger; K Guthke; U Erdmann; U Klein
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

Review 5.  Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck.

Authors:  Murat Bas
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

6.  Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report.

Authors:  Janina Hahn; Susanne Trainotti; Thomas K Hoffmann; Jens Greve
Journal:  Am J Case Rep       Date:  2017-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.